Background Patients with multiple myeloma are at higher risk for infections due to disease
pathogenesis and administered therapies. The purpose of this study was to estimate the risk …

Daratumumab is approved for newly diagnosed or relapsed/refractory multiple myeloma
(MM). The use of daratumumab has improved patient outcomes but has changed the …

The therapeutic options available for patients with multiple myeloma have greatly expanded
over the past decade and incorporating these novel agents into routine clinical practice has …

In multiple myeloma (MM), advancements in treatments and toxicity management have
enhanced survival rates. This, coupled with shifting age demographics in MM, necessitates …

Antibody-mediated rejection (AMR) is among the most frequent causes for graft loss after
kidney transplantation. While there are no approved therapies, several case reports with …

Purpose To report a case of cytomegalovirus (CMV)-related hemorrhagic retinal vasculitis in
a patient with multiple myeloma (MM) on daratumumab, a trial cereblon E3 ligase …

Multiple myeloma (MM) is an incurable plasma cell disorder that affects nearly 35,000
people annually. Over 149,000 individuals are estimated to live in the United States with …

Abstract Patients with Multiple Myeloma have an increased susceptibility to severe infections
due to several various factors, especially the high tumor burden. The use of the anti-CD38 …

Multiple myeloma patients have an increased risk of infections due to both the inherent
nature of the disease and ongoing treatment. We describe the case of a patient who was …

Daratumumab is a widely-used monoclonal anti-CD38 antibody both in newly-diagnosed
and relapsed refractory multiple myeloma. CD38 is expressed on the surface of NK …